The eye’s anatomical and physiological barriers protect against the entry of pathogens and impede drug delivery via permeation.
Conventional topical formulations, such as simple eye drops, require frequent dosing, and typically have less than 5% bioavailability in the eye and poor delivery to its posterior segment. It is possible to deliver APIs to the posterior of the eye via intravitreal injection, but this route suffers from low patient adherence.
Nanoform’s technology enables tight particle size distribution and the desired crystalline or amorphous form. It is the only technology capable of manufacturing nanoparticles at the lower edge of the nano range without solvents, excipients, and complex production processes. The advantages of nanoformed API formulations for ocular delivery include:
- Improved dissolution and solubility
- Longer residence time and sustained release
- Higher bioavailability in the eye
- Better penetration to the posterior segment of the eye
- Minimal irritation of nanosuspensions due to small particle size
- Compared with alternatives, patients have better post-dose visual acuity.
Nanoform’s experience of nanoforming and formulating APIs for ocular delivery includes:
- Aqueous nanosuspension eye drops and injections
- Oil-in-water emulsions and Pickering emulsion-based eye drops
- Thermoresponsive gelling eye drops and injections
- Long acting and smaller implants that need no membrane to reduce initial burst effect.